Advancing peptides for the treatment of rare endocrine and metabolic disorders

We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.



Our lead clinical candidate is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.


We are testing a series of novel, highly potent, small peptide antagonists of the growth hormone (GH) receptor to select a lead development candidate for treatment of acromegaly.

AZP-38XX Acromegal



AZP-3404 is a first-in-class therapeutic peptide that may restore fat and glucose metabolism in the body.


Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.

Press Releases & Recent News

Amolyt Pharma Presents First Clinical Data for AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021)

Download a PDF copy of this press release: EN FR Data from first 4 cohorts of the single ascending dose …

Read More →
Download a PDF: EN or FR

Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021

Download a PDF copy of this press release: EN FR Four abstracts accepted as poster presentations for the Endocrine Society’s …

Read More →
Download a PDF: EN or FR

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.

Scroll to Top